Literature DB >> 108701

Behavioral evidence for supersensitivity after chronic bromocriptine administration.

R C Smith, J R Strong, P B Hicks, T Samorajski.   

Abstract

Behavioral evidence for tolerance and supersensitivity during and after chronic (30 day) administration of bromocriptine (BRC) or bromocriptine + L-dopa in mice was assessed by measuring wheel running (WR) behavior during and after chronic drug administration, and apomorphine- and methylphenidate-(MP-)induced stereotyped gnawing after termination of chronic injections. In both BRC and BRC + L-dopa groups, tolerance developed fairly quickly to the depressing effect of BRC on WR seen on day 1 of drug administration. Mice receiving BRC showed significant increases in WR by week 2 of chronic drug administration, which persisted for at least two days after the termination of chronic injections. During the first week after termination of chronic injections, low doses of both apomorphine and MP induced significantly more stereotyped gnawing in BRC and BRC + L-dopa mice than in the control mice or the mice treated with L-dopa alone. This behavioral evidence for dopaminergic supersensitivity after chronic BRC administration may have relevance for the clinical use of BRC in combination with L-dopa or other dopamine agonists.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 108701     DOI: 10.1007/bf00426662

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  19 in total

1.  Stimulant properties of bromocriptine on central dopamine receptors in comparison to apomorphine, (+)-amphetamine and L-DOPA.

Authors:  A M Johnson; D M Loew; J M Vigouret
Journal:  Br J Pharmacol       Date:  1976-01       Impact factor: 8.739

2.  Binding interactions of ergot alkaloids with monoaminergic receptors in the brain.

Authors:  M Goldstein; J Y Lew; F Hata; A Lieberman
Journal:  Gerontology       Date:  1978       Impact factor: 5.140

3.  Interaction of low-dose amphetamine use with schizophrenia in outpatients: three case reports.

Authors:  A P West
Journal:  Am J Psychiatry       Date:  1974-03       Impact factor: 18.112

4.  Antagonism of methylphenidate-induced stereotyped gnawing in mice.

Authors:  V Pedersen; A V Christensen
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1972

5.  The antiparkinsonian efficacy of bromocriptine.

Authors:  A Lieberman; M Zolfaghari; D Boal; H Hassouri; B Vogel; A Battista; K Fuxe; M Goldstein
Journal:  Neurology       Date:  1976-05       Impact factor: 9.910

6.  Effect of ergot drugs on central catecholamine neurons: evidence for a stimulation of central dopamine neurons.

Authors:  H Corrodi; K Fuxe; T Hökfelt; P Lidbrink; U Ungerstedt
Journal:  J Pharm Pharmacol       Date:  1973-05       Impact factor: 3.765

7.  Comparative psychotomimetic effects of stereoisomers of amphetamine.

Authors:  B M Angrist; B Shopsin; S Gershon
Journal:  Nature       Date:  1971-11-19       Impact factor: 49.962

8.  Bromocriptine and levodopa (with or without carbidopa) in parkinsonism.

Authors:  R Kartzinel; P TEYCHENNE; M M Gillespie; M Perlow; A C Gielen; D A Sadowsky; D B Calne
Journal:  Lancet       Date:  1976-08-07       Impact factor: 79.321

9.  Comparative pharmacokinetic investigations with tritium-labeled ergot alkaloids after oral and intravenous administration man.

Authors:  W H Aellig; E Nüesch
Journal:  Int J Clin Pharmacol Biopharm       Date:  1977-03

10.  Interaction of ergot alkaloids with dopaminergic receptors in the rat striatum and nucleus accumbens.

Authors:  P F Spano; M Trabucchi
Journal:  Gerontology       Date:  1978       Impact factor: 5.140

View more
  6 in total

1.  Locomotor-activating effects of the D2 agonist bromocriptine show environment-specific sensitization following repeated injections.

Authors:  D C Hoffman; R A Wise
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

2.  Lack of cross-sensitization between the locomotor-activating effects of bromocriptine and those of cocaine or heroin.

Authors:  D C Hoffman; R A Wise
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

3.  The effect of chronic bromocriptine and L-dopa on spiperone binding and apomorphine-induced stereotypy.

Authors:  M Globus; J Bannet; B Lerer; R H Belmaker
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

4.  The comparative long-term effects of ciladopa (AY-27,110), a chemically novel dopaminergic agonist, in 6-OHDA-lesioned and intact rats.

Authors:  K Voith
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

5.  Chronic L-DOPA treatment of mice: a behavioural and biochemical study.

Authors:  R Bailey; E Crisp; D M Jackson; O Jenkins
Journal:  J Neural Transm       Date:  1981       Impact factor: 3.575

6.  The effect of amygdala kindling on spontaneous and cocaine-induced motor activity and lidocaine seizures.

Authors:  R M Post; K M Squillace; A Pert; W Sass
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.